- Home
- LVLU vs BYSI Comparison
LVLU vs BYSI Comparison
Compare LVLU & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LVLU | BYSI |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.8M | 35.8M |
| IPO Year | 2021 | 2016 |
Fundamental Metrics
Financial Performance| Metric | LVLU | BYSI |
|---|---|---|
| Price | $11.60 | $0.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 51.3K | ★ 2.0M |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $282,284,000.00 | N/A |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.26 | $0.57 |
| 52 Week High | $32.32 | $2.44 |
Technical Indicators
Market Signals| Indicator | LVLU | BYSI |
|---|---|---|
| Relative Strength Index (RSI) | 40.50 | 30.99 |
| Support Level | $7.60 | $0.57 |
| Resistance Level | $11.99 | $1.25 |
| Average True Range (ATR) | 1.66 | 0.05 |
| MACD | -0.35 | 0.02 |
| Stochastic Oscillator | 14.50 | 21.23 |
Price Performance
Historical ComparisonAbout LVLU Lulu's Fashion Lounge Holdings Inc.
Lulus Fashion Lounge Holdings Inc is a fashion brand serving Millennial and Gen Z women. Its products include Fall Dresses, Winter Dresses, Sweater Dresses, Short Dresses, Casual Dresses, Wedding Dresses, and Denims, among others. The company generates the majority of its revenue from customers based in the United States.
About BYSI BeyondSpring Inc.
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.